TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome
Launched by UNIVERSITY HOSPITAL CENTRE MOTHER TERESA · Jun 10, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or/and the cardiology intensive care unit with a diagnosis of ACS
- Exclusion Criteria:
- • Patients presenting to the cardiology department or/and the cardiology intensive care unit with diagnoses other than ACS and/or UA. Patients who died before undergoing PCI and those who did not provide a contact number.
About University Hospital Centre Mother Teresa
University Hospital Centre Mother Teresa is a leading medical institution dedicated to providing comprehensive healthcare services, advanced clinical research, and medical education. As a prominent academic hospital, it plays a pivotal role in fostering innovation and excellence in patient care, supporting clinical trials that contribute to the advancement of medical knowledge and the development of new treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tirana, , Albania
Patients applied
Trial Officials
Andi Rroku, MD
Principal Investigator
Deutsches Herzzentrum der Charité (DHZC) - Campus Benjamin Franklin
Alban Dibra, Prof. Dr, Phd
Study Director
University of Medicine, Tirana
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported